Study of Allogeneic Blood-derived Natural Killer Cells to Evaluate Safety and Tolerability in Cancer Refractory to Conventional Therapy

Inclusion Criteria: * Pathologically confirmed diagnosis of refractory cancer that has failed at least prior line of conventional standard of care therapy. * Diagnosed with any histologically confirmed malignancy whose disease is confirmed to be metastatic and/or unresectable for which standard curative or beneficial treatments are no longer effective. * Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1. * ≥ 4 weeks since any prior systemic therapy (excluding corticosteroid therapy) to treat the underlying malignancy (standard or investigational). * ≥ 2 weeks since prior palliative radiotherapy. * Complete recovery to baseline or Grade 1 NCI CTCAE v5.0 from AE of prior surgery, radiotherapy, endocrine therapy, and other therapy as applicable, with exception of grade 2 alopecia from prior chemotherapy. * Adequate bone marrow function: * Neutrophils: ≥ 1.5 K/µL without colony-stimulating factor support * Platelet Count: ≥ 100 K/µL * Hemoglobin: ≥ 9.0 g/dL without need for hematopoietic growth factor or transfusion support * No ongoing transfusion requirements * Adequate hepatic function: * Serum total bilirubin ≤ 1.5 × upper limit of normal (ULN), does not apply to patients with Gilbert's syndrome * Serum albumin ≥ 3.0 g/dL * ALT and AST ≤ 2.5 × ULN, unless hepatic metastases are present then \< 5 x ULN * Adequate renal function with creatinine ≤ 2.0 mg/dL. * Coagulation: INR or aPTT ≤1.5 X ULN unless the subject is receiving anticoagulant therapy. * Adequate pulmonary function as assessed by pulse oximetry (\>92% oxygen saturation on room air). * Negative pregnancy test for women of childbearing potential (i.e., all women except those who are post menopause for ≥ 1 year or who have a history of hysterectomy or surgical sterilization) and agree to use of effective contraception (hormonal or barrier method of birth control) during study. * Male participants and female participants of childbearing potential who engage in heterosexual intercourse must agree to use protocol specified method(s) of contraception Exclusion Criteria: * Pregnant and/or lactating females. * Life expectancy of less than three months. * Currently being treated by "biological therapy" as defined by the National Cancer Institute (https://www.cancer.gov/about-cancer/treatment/types/immunotherapy/bio-therapies-fact-sheet) Examples include checkpoint inhibitors, adoptive cell transfer, monoclonal antibodies, treatment vaccines, cytokines, CAR-T therapy, and natural killer (NK) cell therapy. * Participants that are actively positive for COVID. * Autoimmune disease requiring therapy; immunodeficiency, or any disease process requiring immunosuppressive therapy, with exception to the following: * intranasal, inhaled, topical steroids, or local steroid injection (e.g., intra-articular injection); * Systemic corticosteroids at physiologic doses ≤ 10 mg/day of prednisone or equivalent; * Steroids as premedication for hypersensitivity reactions (e.g., CT scan premedication). * Prior clinical trial requiring participant to receive an investigational drug within four weeks of enrollment. * Live vaccine within 30 days prior to enrollment. * Clinically significant (i.e., active) cardiovascular disease: cerebral vascular accident/stroke (\< 6 months prior to enrollment), myocardial infarction (\< 6 months prior to enrollment), unstable angina, congestive heart failure (≥ New York Heart Association Classification Class II), or serious cardiac arrhythmia requiring medication. * Mental or psychological illness preventing cooperation with treatment, efficacy evaluations. * Participants who have undergone prior organ transplantation, including allogeneic stem-cell transplantation.